Idéal Investisseur Connexion Connexion
Français English
CAC 40 : Market closed
7 927,75 pts
-1.89%


Last updated : 20/11/2026 - 17h35 (last close)
Last close data
🏠 Home   ➤    Stock news

bioMérieux Submits FDA Application for Rapid Vaginitis Test

On Friday, bioMérieux submitted a combined 510(k) authorization and CLIA waiver application to the FDA for its Biofire Spotfire Vaginitis Panel, a rapid molecular diagnostic designed to identify the causes of vaginitis in twenty minutes. This move marks the Lyon-based group's entry into the field of women's and sexual health diagnostics.


bioMérieux Submits FDA Application for Rapid Vaginitis Test

A Rapid Molecular Test for Vaginitis Diagnosis

The Biofire Spotfire VG Panel test can identify eight microorganisms responsible for infection (including bacterial vaginosis, several species of Candida, and Trichomonas vaginalis) from a single swab in about twenty minutes, which is the duration of a standard medical consultation. This automated multiplex PCR solution for decentralized biology aims to be used directly at the patient's bedside (point of care), outside of traditional laboratories.

According to bioMérieux, vaginitis is often misdiagnosed with traditional, subjective methods or those lacking sensitivity. The company emphasizes that only about half of the women diagnosed with vaginitis through non-molecular tests receive appropriate treatment.

A First Step in a New Strategic Direction

This FDA authorization request represents bioMérieux's first step into the field of diagnostics in women's and sexual health. It expands the existing portfolio of innovative solutions in decentralized biology, which already includes tests for respiratory infections and sore throats using the same Biofire Spotfire system.

bioMérieux also indicates that the Biofire Spotfire VG Panel test is expected to be submitted for CE marking as a Class C near-patient diagnostic test, in accordance with the IVDR regulation in the European Union. The product is currently not available for sale and is awaiting FDA authorization.

Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning ✓ Euronext data ✓ AI-powered analysis


Sector Diagnostic et services de laboratoire › Diagnostic / labos d'analyse


Context

Period
  • Period: T3 2026
Key reported figures
  • Revenue: 1 042 millions d'euros
  • Quarterly revenue: 1 042 millions d'euros
  • Revenue growth: 9,9 %

The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.

Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.

Advertisement
Every morning
Technical market signals,
before the opening bell.
CAC 40 · SBF 120 · Signals · Analysts
🤖
Today's edition — pre-market
CAC 40
7 702
-0,87%
SBF 120
5 827
-0,87%
📈 Bullish signals
+5,2%
+1,8%
+0,9%
📉 Bearish signals
-14%
-5,7%
🔄 Analyst opinions
▲ 35 €
▼ 80 €
Sign up to see everything →
Before 9 AM every morning
Euronext data
AI-powered analysis





BOURSE · Chaque matin
La synthèse bourse,
avant l'ouverture.
Notre moteur analyse chaque nuit le CAC 40 et le SBF 120. Ce qui mérite attention remonte directement dans votre boîte mail. Gratuit.
✓ Avant 9h00 ✓ 1000+ inscrits ✓ 100% gratuit
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours sur les valeurs Euronext, chaque matin avant 9h.
tendance · 6 séances
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours